Selective Microglial Senescence Targeting via TREM2 Modulation

From Analysis:

Senescent cell clearance as neurodegeneration therapy

Investigate the therapeutic potential of clearing senescent cells (senolytics) to slow or reverse neurodegeneration. Key questions: 1. Which senescent cell types in the brain contribute most to neurodegeneration (microglia, astrocytes, oligodendrocyte precursors)? 2. What senolytic compounds (dasatinib+quercetin, navitoclax, fisetin) show BBB penetration and CNS efficacy? 3. What is the evidence from animal models linking cellular senescence to Alzheimer's, Parkinson's, and other neurodegenerative diseases? 4. What are the risks of removing senescent cells in the aging brain (e.g., loss of SASP-mediated repair signals)? 5. What clinical trials exist or are planned for senolytics in neurodegeneration?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

→ View full analysis & all 7 hypotheses

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

graph TD
    p16INK4a["p16INK4a"] -->|activates| senescence["senescence"]
    SASP["SASP"] -->|activates| neuroinflammation["neuroinflammation"]
    senescence_1["senescence"] -->|contributes to| neurodegeneration["neurodegeneration"]
    p21["p21"] -->|activates| senescence_2["senescence"]
    quercetin["quercetin"] -->|associated with| senolytic_therapy["senolytic_therapy"]
    dasatinib["dasatinib"] -->|associated with| senolytic_therapy_3["senolytic_therapy"]
    senolytic_therapy_4["senolytic_therapy"] -.->|inhibits| senescence_5["senescence"]
    GFAP["GFAP"] -->|co discussed| BMAL1["BMAL1"]
    GFAP_6["GFAP"] -->|co discussed| LRP1["LRP1"]
    GFAP_7["GFAP"] -->|co discussed| APOE["APOE"]
    GFAP_8["GFAP"] -->|co discussed| CLOCK["CLOCK"]
    GFAP_9["GFAP"] -->|co discussed| SIRT1["SIRT1"]
    style p16INK4a fill:#ce93d8,stroke:#333,color:#000
    style senescence fill:#81c784,stroke:#333,color:#000
    style SASP fill:#81c784,stroke:#333,color:#000
    style neuroinflammation fill:#81c784,stroke:#333,color:#000
    style senescence_1 fill:#81c784,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style p21 fill:#ce93d8,stroke:#333,color:#000
    style senescence_2 fill:#81c784,stroke:#333,color:#000
    style quercetin fill:#4fc3f7,stroke:#333,color:#000
    style senolytic_therapy fill:#4fc3f7,stroke:#333,color:#000
    style dasatinib fill:#4fc3f7,stroke:#333,color:#000
    style senolytic_therapy_3 fill:#4fc3f7,stroke:#333,color:#000
    style senolytic_therapy_4 fill:#4fc3f7,stroke:#333,color:#000
    style senescence_5 fill:#81c784,stroke:#333,color:#000
    style GFAP fill:#ce93d8,stroke:#333,color:#000
    style BMAL1 fill:#ce93d8,stroke:#333,color:#000
    style GFAP_6 fill:#ce93d8,stroke:#333,color:#000
    style LRP1 fill:#ce93d8,stroke:#333,color:#000
    style GFAP_7 fill:#ce93d8,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style GFAP_8 fill:#ce93d8,stroke:#333,color:#000
    style CLOCK fill:#ce93d8,stroke:#333,color:#000
    style GFAP_9 fill:#ce93d8,stroke:#333,color:#000
    style SIRT1 fill:#ce93d8,stroke:#333,color:#000